Medisca Secures Settlement With Flacktek, Reinforcing Patent Strength Of MAZ® Mixer

2025-06-10 02:19:01

(MENAFN- AETOSWire) (BUSINESS WIRE )--Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,600, 11,090,224, 11,096,864, 10,231,903, and 10,993,876.

The confidential settlement resolves the pending litigation.“This settlement validates the investment Medisca has made over the past decade in the MAZ innovation and technology,” said Sanjay Goorachurn, CEO of Medisca Pharmaceutique Inc.“We will continue to invest in more innovative products and solutions to meet our customers' evolving needs globally and ensure that new and existing customers receive the high-quality products they deserve."

Medisca remains committed to protecting its intellectual property rights and proprietary technologies. Medisca has ongoing litigations against Fagron B.V., HiperScan GmbH, and Gako Deutschland GmbH for infringement of Medisca German counterpart patents. Those suits were filed in the Munich district court of Germany and request injunctions and monetary remedies.

About Medisca

Medisca is a global corporation with locations throughout North America, Australia, and Europe, that contributes to healthcare by leveraging strong partnerships that deliver customized solutions with an unwavering commitment to quality and innovation. Backed by 30+ years and a strong foundation in pharmaceutical compounding supply, Medisca is a business-to-business company that delivers comprehensive offerings by providing value, consistency, responsiveness, and loyalty.

The Medisca MAZ® mixer provides an efficient, uniform, and high-quality solution for compounding hundreds of formulations and is protected by a robust portfolio of patents across the globe. As Partners in Wellness, Medisca offers an unfailing devotion to improving lives across a multitude of needs and people. For more information, visit and follow us on LinkedIn , Facebook , and YouTube .

View source version on businesswire:

Permalink

MENAFN10062025004146001356ID1109657444

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.